Search results
Results from the WOW.Com Content Network
In September 2023, the FDA approved an updated a monovalent (single) component Omicron variant XBB.1.5 version of the vaccine (Spikevax 2023-2024 formula) as a single dose for individuals aged twelve years of age and older; [203] and authorized the Moderna COVID-19 Vaccine 2023-2024 formula under emergency use for individuals aged 6 months ...
U.S. drug regulators in September found quality control lapses at Moderna’s main factory including with equipment used to manufacture drug substance for its COVID-19 vaccine, according to the ...
Thursday, the FDA granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron ...
(Reuters) -The U.S. Food and Drug Administration (FDA) on Monday authorized updated COVID-19 vaccines from Pfizer/BioNTech and Moderna that target a recently circulating Omicron variant of the ...
As a summer wave of Covid-19 continues to hit the United States, the US Food and Drug Administration on Thursday signed off on updated Covid-19 vaccines from Moderna and Pfizer/BioNTech.
In December 2018, Moderna became a public company via the largest initial public offering of a biotechnology company in history, raising $621 million by selling 27 million shares at $23 per share. [25] [26] The first mRNA vaccine developed by Moderna was for influenza in 2015, and its first antibody encoded by mRNA was in 2019. [6]
The Food and Drug Administration authorized Moderna's Covid-19 vaccine for emergency use Friday, adding a second vaccine to the country's arsenal to fight the pandemic. The United States is the ...
The Moderna COVID-19 vaccine, also known as Spikevax, [318] is an mRNA vaccine [319] produced by the American company Moderna, the U.S. National Institute of Allergy and Infectious Diseases, the U.S. Biomedical Advanced Research and Development Authority, and the Coalition for Epidemic Preparedness Innovations.